Table 2.
HCRU and costs during the 12 months prior to the index datea
| All-cause HCRU, mean (SD) | |
| Number of hospitalizations | 1.7 (3.2) | 
| Length of inpatient stays in days | 16.1 (30.8) | 
| Number of emergency room visits | 0.6 (1.1) | 
| Number of outpatient visits | 88.5 (107.7) | 
| Number of pharmacy fills | 42.5 (19.6) | 
| All-cause total healthcare costs, mean (SD) b | $439,871 ($272,509) | 
| MM-related HCRU, mean (SD) | |
| Number of hospitalizations | 1.4 (2.7) | 
| Length of inpatient stays in days | 15.4 (30.6) | 
| Number of emergency room visits | 0.2 (0.4) | 
| Number of outpatient visits | 69.9 (84.8) | 
| MM-related healthcare costs, mean (SD) b | |
| Inpatient cost | $51,097 ($131,615) | 
| Emergency room cost | $449 ($1,230) | 
| Outpatient cost | $58,850 ($68,016) | 
| MM drug cost | $263,600 ($170,639) | 
| MM drug infusion cost | $11,705 ($12,004) | 
| Stem cell transplant cost | $24,893 ($71,356) | 
| Other costs | $3,730 ($2,460) | 
| Total costs | $414,323 ($260,961) | 
HCRU healthcare resource utilization, LOT line of therapy, MM multiple myeloma, SD standard deviation, TCE triple class exposure
aIndex date, defined as the initiation date of first LOT post-TCE
bAverage cost for all patients in the sample; patients may not have incurred a cost in every category